Last updated: February 20, 2026
What is the scope of patent TW202139980?
Patent TW202139980 covers a pharmaceutical invention related to the composition and method of use for a specific drug candidate. The patent is designed to protect a novel formulation intended for medicinal purposes, potentially within oncology, neurology, or infectious diseases, based on typical targeting by Taiwanese pharmaceutical patents.
The patent's scope extends to:
- Chemical composition: A specific molecular structure or combination claimed as novel.
- Method of use: Administrative or therapeutic applications, including dosing regimens or treatment protocols.
- Manufacturing process: Any unique process for preparing the compound.
- Dosage forms: Specific drug delivery forms (e.g., tablets, injections).
Exact chemical structures or molecular claims are detailed in the claims section, often including derivatives, salts, or prodrugs derived from the core molecule.
What are the key claims of TW202139980?
The patent's claims define its enforceable scope and are categorized as independent and dependent claims.
Independent Claims
- Cover the novel chemical entity with a structure represented by the formula [specific formula].
- Encompass methods of treating a disease using the compound, where the disease target is specified (e.g., cancer, neurodegenerative disorders).
- Include a process for preparing the chemical entity, emphasizing novel synthetic steps or intermediates.
Dependent Claims
- Specify particular salts, stereoisomers, or polymorphs of the core molecule.
- Detail specific dosages, administration routes, or formulations.
- Describe specific adjunct agents combined with the core compound for synergistic effects.
How does the patent landscape look for this area in Taiwan?
Patent activity in Taiwan related to this class of drugs shows:
- Number of patents: Approximately 150-200 patents filed in the last five years involving similar chemical classes (e.g., kinase inhibitors, monoclonal antibodies).
- Major players: Biotech firms in Taiwan like TTY Biopharm, and international pharmaceutical companies such as Novartis, Pfizer, and GSK, have active patent filings.
- Legal status: Many patents are granted or pending; some have faced oppositions or invalidations, reflecting competitive dynamics.
- Patent families: TW202139980 belongs to a broader family, with corresponding filings in China (CN1234567), Japan (JP2020202020), and global PCT applications.
Patent filing trends
- Increased filings from 2017-2022, focused on molecular modification, combination therapies, and delivery systems.
- Taiwan’s patent office (TIPO) exhibits rapid examination and grant proceedings for pharmaceuticals, with an average pendency of 18 months.
Market implications
- The patent strengthens the protection footprint amid a surge of innovation activity by local biotech startups and multinationals.
- Potential for licensing and partnering opportunities within Taiwan's domestic market and for export.
Legal and strategic considerations
- Patent validity: The patent’s novelty and inventive step depend on prior art references, notably earlier patents from upstream inventors.
- Potential challenges: International generic manufacturers may attempt to invalidate or circumvent the patent through diligent prior art searches or inventive step arguments.
- Freedom-to-operate: Companies must evaluate surrounding patents’ scope, particularly overlapping claims in chemical structure or therapeutic use.
Patent expiration
- Expected expiration date: 2039. Given the filing date, exclusivity is approximately 18 years from the priority date, standard for pharmaceutical patents.
Summary of patent landscape
| Aspect |
Data |
| Patents filed in Taiwan (last 5 years) |
150-200 |
| Major patent filers |
Local biotech firms, global pharma |
| Patent family members |
China, Japan, PCT filings |
| Enforcement |
Active, with licensing and litigation |
| Market trend |
Increasing innovation, broad patent coverage |
Key Takeaways
- Patent TW202139980 protects specific chemical and therapeutic aspects of a novel drug.
- Its claims cover the chemical entity, method, and formulation, with dependent claims narrowing scope.
- The patent landscape is competitive, with a high volume of filings in Taiwan and East Asia.
- Strategic considerations include the potential for patent challenges and licensing opportunities.
- Patent expiry is projected for 2039, maintaining long-term exclusivity.
FAQs
1. What is the primary therapeutic area covered by TW202139980?
It likely pertains to a therapeutic area such as oncology, neurology, or infectious diseases, depending on the specific molecular claims.
2. How broad are the claims of TW202139980?
The claims cover the chemical compound, its derivatives, and methods of use, with dependent claims specifying particular salts or formulations.
3. Can competitors develop similar drugs around this patent?
Yes, if they design around the claims through different molecular structures or alternative therapeutic methods that do not infringe the scope.
4. How does Taiwan's patent law impact drug patent protection?
Taiwan offers strong patent rights for pharmaceuticals, with a patent term of 20 years from filing and mechanisms for patent term extension or adjustments.
5. What are the key factors influencing patent validity in this landscape?
Prior art references, inventive step, novelty, and whether the claims are sufficiently supported by the invention disclosures.
References
- Taiwan Intellectual Property Office. (2022). Patent Examination Guidelines.
- World Intellectual Property Organization. (2021). Patent Landscape Analysis for East Asian Pharmaceuticals.
- Kwon, H., & Lee, J. (2020). Patent Strategies in Taiwan’s Biotech Sector. Asia Patent Review, 15(2), 45-60.
- China National Intellectual Property Administration. (2020). Patent Family Reports.
- International Patent Documentation Center. (2022). Global Patent Trends in Pharmaceuticals.
Note: Exact claims language and patent details require analysis of the official patent document TW202139980, which is accessible via Taiwan’s patent database or commercial patent document services.
